Suven Life Sciences, a biopharmaceutical company focused on discovering, developing and commercialising novel pharma products is participating at the 29th J P Morgan Healthcare Conference being held in San Francisco, USA from 10 to 13 January, 2011.

Venkat Jasti, CEO, Suven, is scheduled to discuss the company’s corporate overview, business strategy, fund raising and partnering activity for their phase 2a ready clinical candidate SUVN-502 for cognition in Alzheimer’s and schizophrenia at the J P Morgan Healthcare Conference 2011 where the world’s top notch investment professionals will be present along with the most innovative companies who are decision makers.

J P Morgan Healthcare conference is the premier conference of its kind, bringing together established industry leaders, emerging fast-growth companies, innovative technology creators and globally minded service providers who will deliver presentations to more than 4,000 investors. This conference puts you at the center of the investment and partnering community and provides an open format to connect with the funding partners.

With the targeted audience of senior executives and industry leaders from pharmaceutical, biotechnology and venture capital communities, J P Morgan Healthcare Conference provides the greatest opportunity for relationship building, facilitating discussions on financing opportunities with an unparalleled opportunity to create new value generating partnerships.

Suven has 12 internally discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and schizophrenia.